NEW YORK Nov. 10, 2015 PRNewswire
Dr.David Samadiis proud to introduce an upgraded new MR solution for targeted biopsy of the prostate. Through our recent adoption of the UroNav version 1.2 fusion biopsy system, we can offer a truly new biopsy option for many patients with elevated and/or rising PSA levels. The new UroNav version 1.2 includes many new imaging features and improvements to enhance the clinical needs of patients and further enhance the user experience of the Urologist.
Targeted MR/ultrasound biopsy is poised to become the new standard in prostate care, and Dr.David Samadiis pleased to be one of the first urology groups in the area to offer this powerful solution to our patients. UroNav fuses pre-biopsy MR images of the prostate with ultrasound-guided biopsy images in real time, for excellent delineation of the prostate and suspicious lesions.
After a patient has undergone a prostate MRI, our radiology partners utilize DynaCAD for Prostate to quickly visualize and evaluate suspicious lesions. Our UroNav fusion biopsy system uses this critical diagnostic information to provide our skilled urologists with a targeted approach to prostate biopsy. The fusion of MR and ultrasound images through UroNav gives our urologists the ability to offer their patients an alternative to remaining in an uncertain state of diagnosis after a prostate exam.
“We are confident that this new technology will bring new hope to patients and provide our healthcare providers with the latest technology to identify and target suspicious prostate lesions,” explains Dr.David Samadi, Director of Urology for Your Facility Name.
Other than skin cancer, prostate cancer has become the most common form of cancer in American men and the second-leading cause of cancer death in this population. As 1 man in 6 will be diagnosed with prostate cancer during his lifetime, Dr.David Samadi’sintroduction of MR/ultrasound fusion biopsy could not have come at a more opportune time.
Patients newly diagnosed with prostate cancer can contact world renowned prostate cancer surgeon and urologic oncologist, Dr.David Samadi, for a consultation and to learn more about the Prolaris & Genomic Prostate Score. Visit ProstateCancer911.com and call 212.365.5000 to set up your consultation.
ABOUT DR. DAVID SAMADIDr. Samadi is a board certified urologic oncologist trained in open and traditional and laparoscopic surgery and is an expert in robotic prostate surgery. He is Chairman of Urology, Chief of Robotic Surgery at Lenox Hill Hospital and Professor of Urology at Hofstra North Shore-LIJ School of Medicine. He is also part of the Fox News Medical A Team as a medical correspondent and the Chief Medical Correspondent for am970 in New York City. He has dedicated his distinguished career to the early detection, diagnosis and treatment of prostate cancer and is considered one of the most prominent surgeons in his field. Learn more at prostatecancer911.com. Visit Dr. Samadi’s blog at SamadiMD.com. For more comprehensive information about prostate cancer, detecting prostate cancer, how to live with prostate cancer, and how to help support the fight against prostate cancer, please visit samadifoundation.orgNews